TFA Therapeutics, Inc. SEC filings RAJAF

TFA Therapeutics, Inc. has 38 filings in SEC EDGAR's recent list, going back to Dec 6, 2021. Its latest annual report, Form 20-F, was filed on May 15, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Sep 2, 2026. The company's fiscal year ends on December 31.

TFA Therapeutics, Inc. SEC filings
Form Description Filed Period
NT 20-F Notification of late filing Apr 30, 2026 Dec 31, 2025
NT 20-F Notification of late filing Apr 30, 2025 Dec 31, 2024
UPLOAD Letter from the SEC Nov 8, 2024 —
CORRESP Letter to the SEC Oct 28, 2024 —
UPLOAD Letter from the SEC Sep 4, 2024 —
NT 20-F Notification of late filing Apr 30, 2024 Dec 31, 2023
NT 20-F Extension form Apr 28, 2023 Dec 31, 2022
EFFECT Filing Mar 29, 2023 —
CORRESP Letter to the SEC Mar 27, 2023 —
CORRESP Letter to the SEC Mar 20, 2023 —
UPLOAD Letter from the SEC Mar 17, 2023 —
CORRESP Letter to the SEC Jan 20, 2023 —
UPLOAD Letter from the SEC Dec 21, 2022 —
DRSLTR Filing Dec 8, 2022 —
DRS/A Filing Dec 8, 2022 —
UPLOAD Letter from the SEC Oct 19, 2022 —
DRSLTR Filing Sep 20, 2022 —
DRS/A Filing Sep 20, 2022 —
UPLOAD Letter from the SEC Jan 11, 2022 —
DRS Filing Dec 6, 2021 —

Showing 20 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Medicinal Chemicals & Botanical Products (SIC 2833)
Listed as
RAJAF (OTC)
Fiscal year ends
December 31
Headquarters
Taipei City
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1885680
Former names
Cordyceps Sunshine Biotech Holdings Co., Ltd. (until Jun 25, 2026)

Other Medicinal Chemicals & Botanical Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.